472 related articles for article (PubMed ID: 18980797)
1. Carboxypeptidase U (TAFIa) decreases the efficacy of thrombolytic therapy in ischemic stroke patients.
Brouns R; Heylen E; Sheorajpanday R; Willemse JL; Kunnen J; De Surgeloose D; Hendriks DF; De Deyn PP
Clin Neurol Neurosurg; 2009 Feb; 111(2):165-70. PubMed ID: 18980797
[TBL] [Abstract][Full Text] [Related]
2. Older age does not increase risk of hemorrhagic complications after intravenous and/or intra-arterial thrombolysis for acute stroke.
Pundik S; McWilliams-Dunnigan L; Blackham KL; Kirchner HL; Sundararajan S; Sunshine JL; Tarr RW; Selman WR; Landis DM; Suarez JI
J Stroke Cerebrovasc Dis; 2008 Sep; 17(5):266-72. PubMed ID: 18755405
[TBL] [Abstract][Full Text] [Related]
3. Local proCPU (TAFI) activation during thrombolytic treatment in a dog model of coronary artery thrombosis can be inhibited with a direct, small molecule thrombin inhibitor (melagatran).
Mattsson C; Björkman JA; Abrahamsson T; Nerme V; Schatteman K; Leurs J; Scharpé S; Hendriks D
Thromb Haemost; 2002 Apr; 87(4):557-62. PubMed ID: 12008935
[TBL] [Abstract][Full Text] [Related]
4. Plasma procarboxypeptidase U in men with symptomatic coronary artery disease.
Silveira A; Schatteman K; Goossens F; Moor E; Scharpé S; Strömqvist M; Hendriks D; Hamsten A
Thromb Haemost; 2000 Sep; 84(3):364-8. PubMed ID: 11019956
[TBL] [Abstract][Full Text] [Related]
5. Intravenous thrombolytic therapy for acute ischemic stroke: the experience of a community hospital.
Hsu YC; Sung SF; Ong CT; Wu CS; Su YH
Acta Neurol Taiwan; 2009 Mar; 18(1):14-20. PubMed ID: 19537569
[TBL] [Abstract][Full Text] [Related]
6. Measurement of carboxypeptidase U (active thrombin-activatable fibrinolysis inhibitor) in plasma: Challenges overcome by a novel selective assay.
Heylen E; Van Goethem S; Augustyns K; Hendriks D
Anal Biochem; 2010 Aug; 403(1-2):114-6. PubMed ID: 20371219
[TBL] [Abstract][Full Text] [Related]
7. Safety, effectiveness, and practicality of endovascular therapy within the first 3 hours of acute ischemic stroke onset.
Mathews MS; Sharma J; Snyder KV; Natarajan SK; Siddiqui AH; Hopkins LN; Levy EI
Neurosurgery; 2009 Nov; 65(5):860-5; discussion 865. PubMed ID: 19834397
[TBL] [Abstract][Full Text] [Related]
8. [Thrombolytic therapy in acute ischemic stroke. Critical analysis of current knowledge].
Murray V; Norrving B; Terént A; Wester P
Lakartidningen; 2004 Feb; 101(8):662-8, 670-3. PubMed ID: 15024939
[TBL] [Abstract][Full Text] [Related]
9. Neuroendovascular management of acute ischemic stroke.
Tjoumakaris SI; Jabbour PM; Rosenwasser RH
Neurosurg Clin N Am; 2009 Oct; 20(4):419-29. PubMed ID: 19853801
[TBL] [Abstract][Full Text] [Related]
10. Limited mutagenesis increases the stability of human carboxypeptidase U (TAFIa) and demonstrates the importance of CPU stability over proCPU concentration in down-regulating fibrinolysis.
Knecht W; Willemse J; Stenhamre H; Andersson M; Berntsson P; Furebring C; Harrysson A; Hager AC; Wissing BM; Hendriks D; Cronet P
FEBS J; 2006 Feb; 273(4):778-92. PubMed ID: 16441664
[TBL] [Abstract][Full Text] [Related]
11. Clinical, biochemical and neuroimaging parameters after thrombolytic therapy predict long-term stroke outcome.
Brouns R; Sheorajpanday R; Kunnen J; De Surgeloose D; De Deyn PP
Eur Neurol; 2009; 62(1):9-15. PubMed ID: 19407450
[TBL] [Abstract][Full Text] [Related]
12. Do women benefit more from systemic thrombolysis in acute ischemic stroke? A Serbian experience with thrombolysis in ischemic stroke (SETIS) study.
Jovanović DR; Beslać-Bumbasirević Lj; Budimkić M; Pekmezović T; Zivković M; Kostić VS;
Clin Neurol Neurosurg; 2009 Nov; 111(9):729-32. PubMed ID: 19647928
[TBL] [Abstract][Full Text] [Related]
13. Carboxypeptidase U (CPU, TAFIa, CPB2) in Thromboembolic Disease: What Do We Know Three Decades after Its Discovery?
Claesen K; Mertens JC; Leenaerts D; Hendriks D
Int J Mol Sci; 2021 Jan; 22(2):. PubMed ID: 33477318
[TBL] [Abstract][Full Text] [Related]
14. Procarboxypeptidase U (proCPU, TAFI, proCPB2) in cerebrospinal fluid during ischemic stroke is associated with stroke progression, outcome and blood-brain barrier dysfunction.
Mertens JC; Leenaerts D; Brouns R; Engelborghs S; Ieven M; De Deyn PP; Lambeir AM; Hendriks D
J Thromb Haemost; 2018 Feb; 16(2):342-348. PubMed ID: 29194929
[TBL] [Abstract][Full Text] [Related]
15. Procarboxypeptidase U (TAFI) and the Thr325Ile proCPU polymorphism in patients with hereditary mucocutaneous hemorrhages.
Matus V; Willemse J; Quiroga T; Goycoolea M; Aranda E; Panes O; Pereira J; Hendriks D; Mezzano D
Clin Chim Acta; 2009 Mar; 401(1-2):158-61. PubMed ID: 19038242
[TBL] [Abstract][Full Text] [Related]
16. Combined anti-platelet therapy with aspirin and clopidogrel: risk factor for thrombolysis-related intracerebral hemorrhage in acute ischemic stroke?
Hermann A; Dzialowski I; Koch R; Gahn G
J Neurol Sci; 2009 Sep; 284(1-2):155-7. PubMed ID: 19473668
[TBL] [Abstract][Full Text] [Related]
17. Acute myocardial infarction after thrombolytic treatment of acute ischemic stroke.
Santos N; Serrão M; Silva B; Pereira A; Faria P; Oliveira R; Caires G; Pereira D; Freitas D; Araújo J
Rev Port Cardiol; 2009 Oct; 28(10):1161-6. PubMed ID: 20058780
[TBL] [Abstract][Full Text] [Related]
18. Post-thrombolytic hyperglycemia and 3-month outcome in acute ischemic stroke.
Putaala J; Sairanen T; Meretoja A; Lindsberg PJ; Tiainen M; Liebkind R; Strbian D; Atula S; Artto V; Rantanen K; Silvonen P; Piironen K; Curtze S; Häppölä O; Mustanoja S; Pitkäniemi J; Salonen O; Silvennoinen H; Soinne L; Kuisma M; Tatlisumak T; Kaste M
Cerebrovasc Dis; 2011; 31(1):83-92. PubMed ID: 21079397
[TBL] [Abstract][Full Text] [Related]
19. Recanalization and reperfusion therapies for acute ischemic stroke.
Molina CA; Alvarez-Sabín J
Cerebrovasc Dis; 2009; 27 Suppl 1():162-7. PubMed ID: 19342847
[TBL] [Abstract][Full Text] [Related]
20. Safety of angioplasty and stenting without thrombolysis for the treatment of early ischemic stroke.
Abou-Chebl A; Vora N; Yadav JS
J Neuroimaging; 2009 Apr; 19(2):139-43. PubMed ID: 18826443
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
